SpyGlass Pharma, Inc. (SGP): who owns it and who trades it
As of Nov 16, 2026, SGP insiders reported 7 purchases worth $83.8M in the last 12 months. The largest buyer was RA Capital Healthcare Fund LP (Director), with $59M. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling SpyGlass Pharma
From the latest filingsOverall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SGP
53 funds and institutions reported SGP shares worth $583M at the end of Q2 2026, about 78% of the company. The largest holder is Ra Capital Management, L.P. with 24.0%.
Funds and institutions (13F) 78%Everyone else 22%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 8.02M | 23.99% | $179M | No change |
| NEA Management Company, LLC | 7.39M | 22.11% | $165M | No change |
| Sands Capital Alternatives, LLC | 2.50M | 7.48% | $55.7M | No change |
| Samsara Biocapital, LLC | 2.11M | 6.31% | $47M | No change |
| BlackRock, Inc. | 711,712 | 2.13% | $15.8M | +392% |
| T. Rowe Price Associates | 674,143 | 2.02% | $15M | -4% |
| Vestal Point Capital, LP | 670,000 | 2.00% | $14.9M | +0% |
| JPMorgan Chase & Co | 629,739 | 1.88% | $13.6M | New |
| Deerfield Management Company, L.P. | 550,000 | 1.65% | $12.2M | No change |
| Millennium Management LLC | 507,257 | 1.52% | $11.3M | +8% |
| Aberdeen Group plc | 493,076 | 1.47% | $11M | +124% |
| Vanguard Capital Management LLC | 434,423 | 1.30% | $9.7M | -0% |
| Geode Capital Management, LLC | 277,325 | 0.83% | $6.2M | +119% |
| Franklin Resources Inc | 233,412 | 0.70% | $5.2M | -22% |
| Affinity Asset Advisors, LLC | 131,586 | 0.39% | $2.9M | -47% |
| State Street Corp | 117,561 | 0.35% | $2.6M | +582% |
| Charles Schwab Investment Management Inc | 85,681 | 0.26% | $1.9M | +44% |
| Sixth Street Partners Management Company, L.P. | 85,681 | 0.26% | $1.9M | New |
| Northern Trust Corp | 82,451 | 0.25% | $1.8M | +295% |
| Vanguard Portfolio Management LLC | 75,812 | 0.23% | $1.7M | +1960% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SGP insiders reported $83.8M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | RA Capital Healthcare Fund LP +4 | Director | Purchase | 248,034 | $16.00 | $4M | Form 4 |
| Feb 9, 2026 | RA Capital Healthcare Fund LP +4 | Director | Purchase | 3.44M | $16.00 | $55.1M | Form 4 |
| Feb 9, 2026 | Ali Behbahani | Director | Purchase | 937,500 | $16.00 | $15M | Form 4 |
| Feb 9, 2026 | Geoffrey B Pardo | Director | Purchase | 312,500 | $16.00 | $5M | Form 4 |
| Feb 9, 2026 | Bilal Arshad Khan | Director | Purchase | 20,000 | $16.00 | $320K | Form 4 |
| Feb 9, 2026 | Bilal Arshad Khan | Director | Purchase | 115,000 | $16.00 | $1.8M | Form 4 |
| Feb 9, 2026 | Kirk G. Nielsen | Director | Purchase | 165,000 | $16.00 | $2.6M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| RA Capital Healthcare Fund LP | Director, 10% owner | $59M | – | Feb 9, 2026 |
| Ali Behbahani | Director, 10% owner | $15M | – | Feb 9, 2026 |
| Geoffrey B Pardo | Director | $5M | – | Feb 9, 2026 |
| Kirk G. Nielsen | Director | $2.6M | – | Feb 9, 2026 |
| Bilal Arshad Khan | Director | $2.2M | – | Feb 9, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SGP short interest
Low short interest. 3.5% of SGP shares are sold short: about 1 share in 29. Over the last 12 reports the number of shares short went up 35%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.16M SGP shares were sold short, 3.5% of the shares outstanding, down 5.2% from the report before. At the average daily volume of 96,343 shares, buying them all back would take about 12.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.16M | 3.47% | -5% | 96,343 | 12.1 |
| Oct 15, 2026 | 1.22M | 3.66% | -2% | 78,217 | 15.7 |
| Sep 30, 2026 | 1.25M | 3.75% | +2% | 176,358 | 7.1 |
| Sep 15, 2026 | 1.23M | 3.68% | +12% | 105,648 | 11.6 |
| Aug 31, 2026 | 1.10M | 3.28% | -4% | 69,544 | 15.8 |
| Aug 14, 2026 | 1.14M | 3.40% | -0% | 74,588 | 15.2 |
| Jul 31, 2026 | 1.14M | 3.41% | +1% | 94,553 | 12.1 |
| Jul 15, 2026 | 1.13M | 3.38% | -14% | 142,343 | 7.9 |
| Jun 30, 2026 | 1.31M | 3.92% | +30% | 238,271 | 5.5 |
| Jun 15, 2026 | 1.01M | 3.03% | -12% | 70,786 | 14.3 |
| May 29, 2026 | 1.14M | 3.42% | +33% | 58,858 | 19.4 |
| May 15, 2026 | 858,550 | 2.57% | -3% | 62,319 | 13.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
SpyGlass Pharma company events
SpyGlass Pharma filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 19, 2026.
- Oct 19, 2026AnnouncementSpyGlass Pharma, Inc. issued a press release providing positive interim 4-year data from its first-in-human trial of its Bimatoprost Drug Pad-IOL System. Filing
- Oct 1, 2026AnnouncementThe Company entered into a Stock Purchase Agreement with Santen Holdings US, Inc., a California corporation, and Santen Pharmaceutical Co., Ltd., a Japanese Company. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Mar 9, 2026AnnouncementSpyGlass Pharma, Inc. issued a press release providing positive top-line 12-month clinical updates on its innovative Bimatoprost Drug Pad-IOL System Phase 1/2 trial. Filing
- Feb 13, 2026LeadershipSpyGlass Pharma, Inc. filed a Registration Statement on Form S-1 (File No. 333-292779) with the Securities and Exchange Commission (as amended, the “ Registration Statement ”). Filing
- Feb 9, 2026LeadershipHabib Dable was appointed to the board of directors of SpyGlass Pharma, Inc. on February 5, 2026 in connection with the Company’s initial public offering. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
SpyGlass Pharma financials
Famous investors that hold SGP
1 of the 50 well-known investors we track reported holding SGP in their latest 13F filing. The largest position is Israel Englander's, worth $10.9M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 418,694 | $10.9M | 0.0% | -17% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about SpyGlass Pharma, Inc. (SGP) stock
Who owns the most SGP stock?
The largest reported owner of SpyGlass Pharma, Inc. (SGP) is Ra Capital Management, L.P., with 24.0% of the company. In total, 53 funds and institutions reported holding SGP at the end of Q2 2026, together about 78% of the shares. See the largest owners.
Are SGP insiders buying or selling?
In the last 12 months, SGP insiders reported 7 open-market purchases worth $83.8M and no sales. The latest trade was on Feb 9, 2026. See every trade.
What is the short interest in SGP?
As of Oct 30, 2026, 1.16M SGP shares were sold short, 3.5% of the shares outstanding, down 5.2% from the report before. At the average daily volume of 96,343 shares, buying them all back would take about 12.1 trading days (days to cover). See the history.
Which famous investors hold SGP?
1 of the 50 well-known investors we track reported SGP in their latest 13F filing, including Israel Englander. The largest position is worth $10.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.